Transgene Presents Promising Pre-Clinical Data On TG1050 To Treat Chronic HBV At EASL 2013

Initiation of a Phase I study in 2014. New first in class immunotherapeutic to treat CHB Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection (CHB)... via Health News from Medical News Today Read More Here..